Literature DB >> 11034101

BRCA1 and BRCA2 are necessary for the transcription-coupled repair of the oxidative 8-oxoguanine lesion in human cells.

F Le Page1, V Randrianarison, D Marot, J Cabannes, M Perricaudet, J Feunteun, A Sarasin.   

Abstract

The breast and ovarian cancer susceptibility genes, BRCA1 and BRCA2, are likely to participate in DNA lesion processing. Oxidative lesions, such as 8-oxoguanine, occur in DNA after endogenous or exogenous oxidative stress. We show that deficiency for either BRCA1 or BRCA2 in human cancer cells leads to a block of the RNA polymerase II transcription machinery at the 8-oxoguanine site and impairs the transcription-coupled repair of the lesion, leading to a high mutation rate. Expression of wild-type BRCA1 from a recombinant adenovirus fully complements the repair defect in BRCA1-deficient cells. These results represent the first demonstration of the essential contribution of BRCA1 and BRCA2 gene products in the repair of the 8-oxoguanine oxidative damage specifically located on the transcribed strand in human cells. This suggests that cells from individuals predisposed to breast and/or ovarian cancer may undergo a high rate of mutations because of the deficiency of this damage repair pathway after oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11034101

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  46 in total

1.  Transcription-coupled and DNA damage-dependent ubiquitination of RNA polymerase II in vitro.

Authors:  Keng-Boon Lee; Dong Wang; Stephen J Lippard; Phillip A Sharp
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

Review 2.  Multiple biochemical activities of NM23/NDP kinase in gene regulation.

Authors:  Edith H Postel
Journal:  J Bioenerg Biomembr       Date:  2003-02       Impact factor: 2.945

3.  DNA damage response mediated through BRCA1.

Authors:  Eun Ryoung Jang; Jong-Soo Lee
Journal:  Cancer Res Treat       Date:  2004-08-31       Impact factor: 4.679

4.  BRCA1 and BRCA2 protect against oxidative DNA damage converted into double-strand breaks during DNA replication.

Authors:  Ram Fridlich; Devi Annamalai; Rohini Roy; Giana Bernheim; Simon N Powell
Journal:  DNA Repair (Amst)       Date:  2015-03-17

5.  BRCA1/BARD1 inhibition of mRNA 3' processing involves targeted degradation of RNA polymerase II.

Authors:  Frida E Kleiman; Foon Wu-Baer; Danae Fonseca; Syuzo Kaneko; Richard Baer; James L Manley
Journal:  Genes Dev       Date:  2005-05-15       Impact factor: 11.361

6.  Homologous recombination is involved in transcription-coupled repair of UV damage in Saccharomyces cerevisiae.

Authors:  Abdelilah Aboussekhra; Ibtehaj S Al-Sharif
Journal:  EMBO J       Date:  2005-05-19       Impact factor: 11.598

Review 7.  Phospho-Ser/Thr-binding domains: navigating the cell cycle and DNA damage response.

Authors:  H Christian Reinhardt; Michael B Yaffe
Journal:  Nat Rev Mol Cell Biol       Date:  2013-09       Impact factor: 94.444

8.  Loss of Bard1, the heterodimeric partner of the Brca1 tumor suppressor, results in early embryonic lethality and chromosomal instability.

Authors:  Ellen E McCarthy; Julide T Celebi; Richard Baer; Thomas Ludwig
Journal:  Mol Cell Biol       Date:  2003-07       Impact factor: 4.272

9.  Hyperphosphorylation of RNA polymerase II in response to topoisomerase I cleavage complexes and its association with transcription- and BRCA1-dependent degradation of topoisomerase I.

Authors:  Olivier Sordet; Stéphane Larochelle; Estelle Nicolas; Ellen V Stevens; Chao Zhang; Kevan M Shokat; Robert P Fisher; Yves Pommier
Journal:  J Mol Biol       Date:  2008-06-17       Impact factor: 5.469

10.  Molecular analysis of the APC and MUTYH genes in Galician and Catalonian FAP families: a different spectrum of mutations?

Authors:  Nuria Gómez-Fernández; Sergi Castellví-Bel; Ceres Fernández-Rozadilla; Francesc Balaguer; Jenifer Muñoz; Irene Madrigal; Montserrat Milà; Begoña Graña; Ana Vega; Antoni Castells; Angel Carracedo; Clara Ruiz-Ponte
Journal:  BMC Med Genet       Date:  2009-06-16       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.